HCC
Latest News
Latest Videos
CME Content
More News
During a Targeted Oncology Case-Based Peer Perspectives event, Catherine Frenette, MD, discussed the case of a 77-year-old patients with hepatocellular carcinoma.
In an interview with Targeted Oncology, Richard S. Finn, MD, discussed the real-world data from the REFINE study, which is exploring the outcomes of patients with unresectable hepatocellular carcinoma who received treatment with regorafenib.
Efficacy, safety, and quality of life data from IMbrave150 have changed the standard of care for unresectable hepatocellular carcinoma.
Recent updates from the IMbrave150 study, which led to the FDA approval of frontline atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [HCC].
Richard S. Finn, MD, provides an overview of the systemic treatment options for advanced unresectable hepatocellular carcinoma.
Defining resectability in hepatocellular carcinoma based on burden of liver disease and Child-Pugh score.
A review of prognostic factors and the importance of understanding underlying liver disease to help stage and treat patients with hepatocellular carcinoma.
Richard S. Finn, MD, provides insight on the key risk factors that lead to hepatocellular carcinoma.
Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.
Unique challenges and opportunities for the treatment and management of patients with hepatocellular carcinoma have been identified by the Association of Community Cancer Centers in an analysis.
Al B. Benson, MD, discusses recent developments for the treatment of patient with hepatocellular carcinoma with systemic therapy in the first and second line.
New data showed the Helio Liver Test demonstrated high accuracy and screening value of this cell-free DNA methylation blood-based assay for the detection of hepatocellular carcinoma.
Laura M. Kulik, MD, talked through diagnosing a 77-year-old female patients with hepatocellular carcinoma as well as the treatment options for her disease during a Targeted Oncology Case Based Peer Perspectives event.
